Baxalta: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
Tags: mobile edit mobile web edit
 
CSV import
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
[[File:Baxalta logo.jpg|thumb|Baxalta logo]] '''Baxalta Incorporated''' was a biopharmaceutical company that specialized in developing, manufacturing, and commercializing therapies for orphan diseases and underserved conditions in hematology, immunology, and oncology. The company was a spin-off from [[Baxter International]] and became an independent entity on July 1, 2015.


==History==
{{Infobox company
Baxalta was created as a result of a corporate spin-off from [[Baxter International]], a global healthcare company. The spin-off was aimed at focusing on the development and commercialization of biopharmaceutical products. On January 11, 2016, [[Shire (pharmaceutical company)|Shire]] announced that it would acquire Baxalta for $32 billion. The acquisition was completed on June 3, 2016, and Baxalta was integrated into Shire.
| name = Baxalta
| logo = <!-- Logo image file name -->
| type = Subsidiary
| industry = [[Biotechnology]]
| founded = 2015
| defunct = 2016
| fate = Acquired by [[Shire (pharmaceutical company)|Shire]]
| headquarters = [[Bannockburn, Illinois]], [[United States]]
| key_people = [[Ludwig Hantson]] (CEO)
| products = [[Hemophilia]] treatments, [[immunology]] products
| parent = [[Shire (pharmaceutical company)|Shire]]
}}


==Products and Services==
'''Baxalta Incorporated''' was a biopharmaceutical company that specialized in developing and marketing therapies for [[hematology]], [[immunology]], and [[oncology]]. It was established in 2015 as a spin-off from [[Baxter International]].
Baxalta's product portfolio included treatments for rare and chronic conditions in the following therapeutic areas:


===Hematology===
== History ==
Baxalta developed therapies for bleeding disorders, including hemophilia. Their products included recombinant and plasma-derived therapies for the treatment of hemophilia A and B.
Baxalta was created when [[Baxter International]] decided to spin off its biopharmaceutical division to focus on its medical products business. The spin-off was completed on July 1, 2015, and Baxalta began trading on the [[New York Stock Exchange]] under the ticker symbol BXLT.


===Immunology===
In January 2016, [[Shire (pharmaceutical company)|Shire]] announced it would acquire Baxalta for $32 billion. The acquisition was completed in June 2016, and Baxalta became a wholly owned subsidiary of Shire.
The company offered treatments for primary immunodeficiency disorders and other immune system-related conditions. These included immunoglobulin therapies and other biologics.


===Oncology===
== Products ==
Baxalta's oncology division focused on developing treatments for various types of cancer, including hematologic malignancies and solid tumors. Their pipeline included both marketed products and investigational therapies.
Baxalta's product portfolio included treatments for [[hemophilia]], [[immune disorders]], and [[cancer]]. Some of its notable products were:
* [[Advate]] - a recombinant antihemophilic factor for [[hemophilia A]]
* [[Gammagard]] - an [[immunoglobulin]] therapy for primary immunodeficiency
* [[Oncaspar]] - a treatment for [[acute lymphoblastic leukemia]]


==Research and Development==
== Research and Development ==
Baxalta invested significantly in research and development to advance its pipeline of innovative therapies. The company collaborated with various academic institutions, research organizations, and other biopharmaceutical companies to enhance its R&D capabilities.
Baxalta invested heavily in [[research and development]] to expand its product offerings and improve existing therapies. The company focused on developing treatments for rare and orphan diseases, leveraging its expertise in [[biotechnology]] and [[genetic engineering]].


==Corporate Structure==
== See also ==
Baxalta was headquartered in [[Bannockburn, Illinois]]. The company operated globally, with a presence in over 100 countries. It employed approximately 16,000 people worldwide.
 
==Acquisition by Shire==
The acquisition by [[Shire (pharmaceutical company)|Shire]] was part of a strategic move to create a global leader in rare diseases and highly specialized conditions. The combined entity aimed to leverage Baxalta's expertise in hematology and immunology with Shire's existing portfolio and capabilities.
 
==See Also==
* [[Baxter International]]
* [[Baxter International]]
* [[Shire (pharmaceutical company)]]
* [[Shire (pharmaceutical company)]]
* [[Biopharmaceutical]]
* [[Biotechnology]]
* [[Hematology]]
* [[Pharmaceutical industry]]
* [[Immunology]]
* [[Oncology]]


==References==
== References ==
{{Reflist}}
<references />


==External Links==
== External links ==
{{Commons category|Baxalta}}
* [Official website of Shire](https://www.shire.com)


[[Category:Biopharmaceutical companies]]
[[Category:Biotechnology companies of the United States]]
[[Category:Defunct pharmaceutical companies]]
[[Category:Defunct companies based in Illinois]]
[[Category:Companies established in 2015]]
[[Category:Companies established in 2015]]
[[Category:Companies disestablished in 2016]]
[[Category:Companies disestablished in 2016]]
[[Category:2015 establishments in Illinois]]
[[Category:Shire (pharmaceutical company)]]
[[Category:2016 disestablishments in Illinois]]
== Baxalta ==
 
<gallery>
{{Pharma-stub}}
File:Baxalta_logo.svg|Baxalta logo
</gallery>

Latest revision as of 00:01, 25 February 2025


Baxalta







TypeSubsidiary
Key peopleLudwig Hantson (CEO)
IndustryBiotechnology
ProductsHemophilia treatments, immunology products



Baxalta Incorporated was a biopharmaceutical company that specialized in developing and marketing therapies for hematology, immunology, and oncology. It was established in 2015 as a spin-off from Baxter International.

History[edit]

Baxalta was created when Baxter International decided to spin off its biopharmaceutical division to focus on its medical products business. The spin-off was completed on July 1, 2015, and Baxalta began trading on the New York Stock Exchange under the ticker symbol BXLT.

In January 2016, Shire announced it would acquire Baxalta for $32 billion. The acquisition was completed in June 2016, and Baxalta became a wholly owned subsidiary of Shire.

Products[edit]

Baxalta's product portfolio included treatments for hemophilia, immune disorders, and cancer. Some of its notable products were:

Research and Development[edit]

Baxalta invested heavily in research and development to expand its product offerings and improve existing therapies. The company focused on developing treatments for rare and orphan diseases, leveraging its expertise in biotechnology and genetic engineering.

See also[edit]

References[edit]

<references />

External links[edit]

Baxalta[edit]

  • Baxalta logo
    Baxalta logo
Retrieved from "https://wikimd.com/index.php?title=Baxalta&oldid=6343956"